SCHEMBL164161

SCHEMBL164161

Cn1ccnc1C(=O)NCC(=O)N1CCN(c2ccccc2-c2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.49
KMT2A Q03164 2/20 0.49
CXCR3 P49682 1/20 0.48
KCNH2 Q12809 1/20 0.48
GFER P55789 2/20 0.45
DRD2 P14416 5/20 0.44
HTR1A P08908 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 1/20 0.44
F2 P00734 1/20 0.44
HTR7 P34969 2/20 0.43
HTR6 P50406 1/20 0.43
POLB P06746 2/20 0.43
TP53 P04637 2/20 0.43
ATM Q13315 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15911444 0.84 CXCR3 (0.47) RAB9AKMT2ACXCR3KCNH2DRD2
SCHEMBL13039593 0.82 RAB9A (0.52) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL13039590 0.81 KMT2A (0.50) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL165214 0.81 GFER (0.51) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL3739089 0.81 KMT2A (0.73) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL13039609 0.78 CXCR3 (0.58) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL13039602 0.77 KCNH2 (0.60) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL13039483 0.76 RAB9A (0.47) RAB9AKMT2ACXCR3KCNH2DRD2
SCHEMBL13039607 0.76 RAB9A (0.51) RAB9AKMT2ACXCR3KCNH2GFER
SCHEMBL13039608 0.75 CXCR3 (0.50) RAB9AKMT2ACXCR3KCNH2GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424840-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP claimed
EP-2424840-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-08-06 EP disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
EP-2424840-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 RAB9A 1661/4885KMT2A 4032/4885CXCR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.